Pierre Fabre S.a.

Pierre Fabre Medicament

P. F. Medicament

Lucien Dussourd d'Hinterland

Gerard Normier

Anne-Marie Pinel

Henri Cousse

Gilbert Mouzin

Hans Binz

Jacques Durand

Alain Le Pape

Michel Favaron

Jean-Claude Vezin

Jacques Dubois

Souhail Delassan

The present invention relates to a D 25 polysaccharide compound whose lipid has been partially removed and to its derivatives, wherein at least 85% by weight, preferably 90% of the compound, exists in aqueous solution in monomeric form. The 30 kD molecular weight polysaccharide compound extracted from the membrane proteoglycan of the bacterium Klebsiella pneumoniae is mentioned in particular. The amount of palmitic fatty acids which is bound to it in esterified form does not exceed 0.01% by weight of the compound and the amount of palmitic fatty acids which is associated with it in the free form does not exceed 0.1% by weight of the compound.

Partially delipidated D25 polysaccaride composition for imaging and

The invention relates to a polysaccharide derivative which is an amide, an ester, an ether, a salt or a quaternary ammonium derivative of D.25 with an amine, an acid or an alcohol.

Immunomodulators obtained semisynthetically from a bacterial

The present invention relates to a membrane polysaccharide of bacterial origin having the following quantitative analytical composition:

Membrane polysaccharides which are useful as immunostimulants

The present invention relates to a method of preparing bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram-negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product. The products obtained are useful as a medicament.

Method of preparing immunostimulant proteoglycans which induce

Immunostimulating preparations based on ribosomal RNA's and a process

The present invention relates to an improved process for the preparation of plasminogen activator. This is a process for separating a plasminogen activator according to U.S. Pat. No. 3,998,947 characterized in that it comprises at least the following stages:

Process for obtaining a plasminogen activator

The present invention relates to new chemical compounds which can be used as inhibitors of dental plaque, and orally-acceptable compositions thereof, combinations thereof with known compounds having an inhibitory action on the formation of dental plaque, such as biguanidines, and method of treating therewith for the prevention of dental plaque or tartar and dental caries. The new compounds have the general formula ##STR1## in which R.sub.1 = H or alkyl

Growing community of inventors

Castres, France

Lucien Dussourd d'Hinterland